Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > can't win in the ate market

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Mar 10, 2021 4:41pm

178 Views

Post# 32765515

RE:can't win in the ate market

Anything below $6 is a bargain as you already beat the PP price. Anything below $5? It will disappear within a second with any positive NRs. Any positive NRs we can rely on? A lot! Ph3 346, fast track 352, IND 340, new pipeline for IBD, etc. Any future PP needed? No, as ATE has c$74M cash in bank. The future of ATE is bright and certain. So, my advice is, accumulating more when you can at this price. GLTA longs!

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth